Literature DB >> 22017435

Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease.

Robert C Rickert1, Julia Jellusova, Ana V Miletic.   

Abstract

Members of the tumor necrosis factor receptor superfamily (TNFRSF) participate prominently in B-cell maturation and function. In particular, B-cell activating factor belonging to the TNF family receptor (BAFF-R), B-cell maturation antigen (BCMA), and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) play critical roles in promoting B-cell survival at distinct stages of development by engaging a proliferation-inducing ligand (APRIL) and/or BAFF. CD40 is also essential for directing the humoral response to T-cell-dependent antigens. Signaling by the TNFRSF is mediated primarily, albeit not exclusively, via the TNFR-associated factor (TRAF) proteins and activation of the canonical and/or non-canonical nuclear factor-κB (NF-κB) pathways. Dysregulated signaling by TNFRSF members can promote B-cell survival and proliferation, causing autoimmunity and neoplasia. In this review, we present a current understanding of the functions of and distinctions between APRIL/BAFF signaling by their respective receptors expressed on particular B-cell subsets. These findings are compared and contrasted with CD40 signaling, which employs similar signaling conduits to achieve distinct cellular outcomes in the context of the germinal center response. We also underscore how new findings and conceptual insights into TNFRSF signaling are facilitating the understanding of B-cell malignancies and autoimmune diseases.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017435      PMCID: PMC3202302          DOI: 10.1111/j.1600-065X.2011.01067.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  231 in total

1.  Mcl-1 is essential for germinal center formation and B cell memory.

Authors:  Ingela Vikstrom; Sebastian Carotta; Katja Lüthje; Victor Peperzak; Philipp J Jost; Stefan Glaser; Meinrad Busslinger; Philippe Bouillet; Andreas Strasser; Stephen L Nutt; David M Tarlinton
Journal:  Science       Date:  2010-10-07       Impact factor: 47.728

2.  Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies.

Authors:  Stephen A Mihalcik; Renee C Tschumper; Diane F Jelinek
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

3.  B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-kappaB2.

Authors:  Iris Castro; Jacqueline A Wright; Bazarragchaa Damdinsuren; Kristen L Hoek; Gianluca Carlesso; Nicholas P Shinners; Rachel M Gerstein; Robert T Woodland; Ranjan Sen; Wasif N Khan
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

4.  Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus.

Authors:  Van Trung Chu; Philipp Enghard; Stefanie Schürer; Gudrun Steinhauser; Birgit Rudolph; Gabriela Riemekasten; Claudia Berek
Journal:  Arthritis Rheum       Date:  2009-07

Review 5.  Non-canonical NF-κB signaling pathway.

Authors:  Shao-Cong Sun
Journal:  Cell Res       Date:  2010-12-21       Impact factor: 25.617

6.  The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency.

Authors:  John J Lee; Haifa H Jabara; Lilit Garibyan; Ingrid Rauter; Tatyana Sannikova; Stacey R Dillon; Richard Bram; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2010-12       Impact factor: 10.793

7.  Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways.

Authors:  Lan V Pham; Lingchen Fu; Archito T Tamayo; Carlos Bueso-Ramos; Elias Drakos; Francisco Vega; L Jeffrey Medeiros; Richard J Ford
Journal:  Blood       Date:  2010-10-01       Impact factor: 22.113

8.  Eosinophils are required for the maintenance of plasma cells in the bone marrow.

Authors:  Van Trung Chu; Anja Fröhlich; Gudrun Steinhauser; Tobias Scheel; Toralf Roch; Simon Fillatreau; James J Lee; Max Löhning; Claudia Berek
Journal:  Nat Immunol       Date:  2011-01-09       Impact factor: 25.606

Review 9.  A single NFκB system for both canonical and non-canonical signaling.

Authors:  Vincent Feng-Sheng Shih; Rachel Tsui; Andrew Caldwell; Alexander Hoffmann
Journal:  Cell Res       Date:  2010-11-23       Impact factor: 25.617

Review 10.  Cracking the BAFF code.

Authors:  Fabienne Mackay; Pascal Schneider
Journal:  Nat Rev Immunol       Date:  2009-07       Impact factor: 53.106

View more
  135 in total

1.  Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.

Authors:  Shannon L Haley; Evgeni P Tzvetkov; Samantha Meuwissen; Joseph R Plummer; James P McGettigan
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Targeting F box protein Fbxo3 to control cytokine-driven inflammation.

Authors:  Rama K Mallampalli; Tiffany A Coon; Jennifer R Glasser; Claire Wang; Sarah R Dunn; Nathaniel M Weathington; Jing Zhao; Chunbin Zou; Yutong Zhao; Bill B Chen
Journal:  J Immunol       Date:  2013-10-11       Impact factor: 5.422

3.  Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity.

Authors:  Debra D Bloom; Sofiya Reshetylo; Cassandra Nytes; Claudia T Goodsett; Peiman Hematti
Journal:  J Immunother       Date:  2018-06       Impact factor: 4.456

Review 4.  The regulation of gut mucosal IgA B-cell responses: recent developments.

Authors:  N Y Lycke; M Bemark
Journal:  Mucosal Immunol       Date:  2017-07-26       Impact factor: 7.313

5.  DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.

Authors:  Sachin Gupta; Emily S Clark; James M Termini; Justin Boucher; Saravana Kanagavelu; Celia C LeBranche; Sakhi Abraham; David C Montefiori; Wasif N Khan; Geoffrey W Stone
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

6.  CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

Authors:  Julia Bluhm; Elisa Kieback; Stephen F Marino; Felix Oden; Jörg Westermann; Markus Chmielewski; Hinrich Abken; Wolfgang Uckert; Uta E Höpken; Armin Rehm
Journal:  Mol Ther       Date:  2018-06-18       Impact factor: 11.454

7.  Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus.

Authors:  Lino L Teichmann; Dominik Schenten; Ruslan Medzhitov; Michael Kashgarian; Mark J Shlomchik
Journal:  Immunity       Date:  2013-03-14       Impact factor: 31.745

8.  Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Authors:  Caron A Jacobson; Lixian Sun; Haesook T Kim; Sean M McDonough; Carol G Reynolds; Michael Schowalter; John Koreth; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742

9.  IFN-β treatment requires B cells for efficacy in neuroautoimmunity.

Authors:  Ryan D Schubert; Yang Hu; Gaurav Kumar; Spencer Szeto; Peter Abraham; Johannes Winderl; Joel M Guthridge; Gabriel Pardo; Jeffrey Dunn; Lawrence Steinman; Robert C Axtell
Journal:  J Immunol       Date:  2015-02-02       Impact factor: 5.422

10.  The B Cell-Stimulatory Cytokines BLyS and APRIL Are Elevated in Human Periodontitis and Are Required for B Cell-Dependent Bone Loss in Experimental Murine Periodontitis.

Authors:  Toshiharu Abe; Mohammed AlSarhan; Manjunatha R Benakanakere; Tomoki Maekawa; Denis F Kinane; Michael P Cancro; Jonathan M Korostoff; George Hajishengallis
Journal:  J Immunol       Date:  2015-07-06       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.